These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

127 related articles for article (PubMed ID: 12519069)

  • 1. The role of the side chain in determining relative delta- and kappa-affinity in C5'-substituted analogues of naltrindole.
    Black SL; Jales AR; Brandt W; Lewis JW; Husbands SM
    J Med Chem; 2003 Jan; 46(2):314-7. PubMed ID: 12519069
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Selective kappa-opioid antagonists related to naltrindole. Effect of side-chain spacer in the 5'-amidinoalkyl series.
    Jales AR; Husbands SM; Lewis JW
    Bioorg Med Chem Lett; 2000 Oct; 10(20):2259-61. PubMed ID: 11055333
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Synthesis, opioid receptor binding, and bioassay of naltrindole analogues substituted in the indolic benzene moiety.
    Ananthan S; Johnson CA; Carter RL; Clayton SD; Rice KC; Xu H; Davis P; Porreca F; Rothman RB
    J Med Chem; 1998 Jul; 41(15):2872-81. PubMed ID: 9667975
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Reporter affinity labels: an o-phthalaldehyde derivative of beta-naltrexamine as a fluorogenic ligand for opioid receptors.
    Le Bourdonnec B; El Kouhen R; Lunzer MM; Law PY; Loh HH; Portoghese PS
    J Med Chem; 2000 Jun; 43(13):2489-92. PubMed ID: 10891107
    [No Abstract]   [Full Text] [Related]  

  • 5. A bivalent ligand (KDAN-18) containing delta-antagonist and kappa-agonist pharmacophores bridges delta2 and kappa1 opioid receptor phenotypes.
    Daniels DJ; Kulkarni A; Xie Z; Bhushan RG; Portoghese PS
    J Med Chem; 2005 Mar; 48(6):1713-6. PubMed ID: 15771416
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A remarkable change of opioid receptor selectivity on the attachment of a peptidomimetic kappa address element to the delta antagonist, natrindole: 5'-[N2-alkylamidino)methyl]naltrindole derivatives as a novel class of kappa opioid receptor antagonists.
    Olmsted SL; Takemori AE; Portoghese PS
    J Med Chem; 1993 Jan; 36(1):179-80. PubMed ID: 8380614
    [No Abstract]   [Full Text] [Related]  

  • 7. The design of delta-selective opioid receptor antagonists.
    Portoghese PS
    Farmaco; 1993 Feb; 48(2):243-51. PubMed ID: 8388215
    [TBL] [Abstract][Full Text] [Related]  

  • 8. delta Opioid affinity and selectivity of 4-hydroxy-3-methoxyindolomorphinan analogues related to naltrindole.
    Coop A; Rothman RB; Dersch C; Partilla J; Porreca F; Davis P; Jacobson AE; Rice KC
    J Med Chem; 1999 May; 42(9):1673-9. PubMed ID: 10229636
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Synthesis and delta-opioid receptor antagonist activity of a naltrindole analogue with a regioisomeric indole moiety.
    Portoghese PS; Ohkawa S; Moe ST; Takemori AE
    J Med Chem; 1994 Jun; 37(12):1886-8. PubMed ID: 8021929
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Synthesis and biological activity of 3-substituted 3-desoxynaltrindole derivatives.
    Kubota H; Rothman RB; Dersch C; McCullough K; Pinto J; Rice KC
    Bioorg Med Chem Lett; 1998 Apr; 8(7):799-804. PubMed ID: 9871544
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Importance of phenolic address groups in opioid kappa receptor selective antagonists.
    Thomas JB; Fix SE; Rothman RB; Mascarella SW; Dersch CM; Cantrell BE; Zimmerman DM; Carroll FI
    J Med Chem; 2004 Feb; 47(4):1070-3. PubMed ID: 14761209
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A bivalent ligand (KDN-21) reveals spinal delta and kappa opioid receptors are organized as heterodimers that give rise to delta(1) and kappa(2) phenotypes. Selective targeting of delta-kappa heterodimers.
    Bhushan RG; Sharma SK; Xie Z; Daniels DJ; Portoghese PS
    J Med Chem; 2004 Jun; 47(12):2969-72. PubMed ID: 15163177
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Selective delta-opioid receptor ligands: potential PET ligands based on naltrindole.
    Clayson J; Jales A; Tyacke RJ; Hudson AL; Nutt DJ; Lewis JW; Husbands SM
    Bioorg Med Chem Lett; 2001 Apr; 11(7):939-43. PubMed ID: 11294396
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Extension of the Nenitzescu reaction to simple ketones provides an efficient route to 1'-alkyl-5'-hydroxynaltrindole analogues, potent and selective delta-opioid receptor antagonists.
    Shefali S; Srivastava SK; Husbands SM; Lewis JW
    J Med Chem; 2005 Jan; 48(2):635-8. PubMed ID: 15658877
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Pharmacological properties of bivalent ligands containing butorphan linked to nalbuphine, naltrexone, and naloxone at mu, delta, and kappa opioid receptors.
    Peng X; Knapp BI; Bidlack JM; Neumeyer JL
    J Med Chem; 2007 May; 50(9):2254-8. PubMed ID: 17407276
    [TBL] [Abstract][Full Text] [Related]  

  • 16. (E)- and (Z)-7-arylidenenaltrexones: synthesis and opioid receptor radioligand displacement assays.
    Palmer RB; Upthagrove AL; Nelson WL
    J Med Chem; 1997 Feb; 40(5):749-53. PubMed ID: 9057861
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Synthesis and evaluation of novel opioid ligands with a C-homomorphinan skeleton.
    Ishikawa K; Mochizuki Y; Hirayama S; Nemoto T; Nagai K; Itoh K; Fujii H
    Bioorg Med Chem; 2016 May; 24(10):2199-205. PubMed ID: 27079125
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Potent and selective indolomorphinan antagonists of the kappa-opioid receptor.
    Stevens WC; Jones RM; Subramanian G; Metzger TG; Ferguson DM; Portoghese PS
    J Med Chem; 2000 Jul; 43(14):2759-69. PubMed ID: 10893314
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The in vitro pharmacological profile of TD-1211, a neutral opioid receptor antagonist.
    Tsuruda PR; Vickery RG; Long DD; Armstrong SR; Beattie DT
    Naunyn Schmiedebergs Arch Pharmacol; 2013 Jun; 386(6):479-91. PubMed ID: 23549670
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Expression and localization of delta-, kappa-, and mu-opioid receptors in human spermatozoa and implications for sperm motility.
    Agirregoitia E; Valdivia A; Carracedo A; Casis L; Gil J; Subiran N; Ochoa C; Irazusta J
    J Clin Endocrinol Metab; 2006 Dec; 91(12):4969-75. PubMed ID: 16984994
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.